Skip to main content
All Posts By

admin

university-of-maryland-umd-logo

University Senate to transform non-tenure-track faculty policies – The Diamondback

By News Archive

university-of-maryland-umd-logo

The University Senate made progress on the policies and guidelines that address non-tenure-track faculty — or professional track faculty, as they will soon be addressed, after a proposal passed in the senate yesterday.

The proposal, which passed by a vote of 61–12 with four abstentions, aims to create an overall title for faculty who are not on the tenure track but contribute to the university through teaching, research or service.

Read More
real-estate-market-increase-sxc

Alexandria Real Estate Equities Rides the Biotech Innovation Boom – REIT.com

By News Archive

real-estate-market-increase-sxc

As Alexandria Real Estate Equities (NYSE: ARE) marks the 20th anniversary of its founding, the provider of state-of-the-art real estate for the science and technology industries is seeing occupancy, demand and new development all reach record levels.

“It’s an interesting time because we’re seeing the innovation economy doing miraculously well,” said Joel Marcus, founder and CEO of Pasadena, Calif.-based Alexandria.

Read More
roche-logo

Roche acquires exclusive rights to AbVitro’s extension-based target enrichment technology

By News Archive

roche-logo

Swiss drug major Roche (ROG: SIX) has acquired exclusive rights to a primer extension-based target enrichment technology and associated patent applications filled by therapeutic target discovery company AbVitro.

AbVitro and Roche scientists are to collaborate on the development and application of the technology, which will be used to support next-generation sequencing directly from blood or other biological samples, a key advantage for clinical sequencing applications. It will be incorporated into Roche’s sequencing unit research and development pipeline to support the strategy of providing a full next-generation sequencing workflow solution for clinical sequencing.

Read More
nih-new-logo

NIH Awards $32-Million to Tackle Big Data in Medicine – Research – The Chronicle of Higher Education

By News Archive

nih-new-logo

The National Institutes of Health on Thursday awarded almost $32-million in grants to more than two dozen institutions to devise innovative ways of helping researchers handle huge sets of data seen as increasingly central to future medical discoveries.

The grants are the first outlay in a project, announced last year and known as Big Data to Knowledge, that’s expected to involve more than $600-million in spending by 2020. Its goals include developing and distributing methods, software, and tools for sharing, analyzing, managing, and integrating data into medical research.

Read More
NewImage

BioBuzz MoCo October 22nd

By News Archive

NewImage

Join the BioBuzz networking group at our next free event. Along with 100’s of the region’s bioscience workers, you too could be making new connections, getting jobs and helping to build a stronger, more connected industry through the BioBuzz community!

The event is always free and we offer free drinks to the first 50 to 100 who arrive depending on how much we’ve been sponsored on a given month. People from all around the the region are coming out each month for this unique and welcoming monthly happy hour. It’s a great place to meet up with coworkers past and present, make new connections or just catch up on the latest industry gossip If you’re new and haven’t yet made it out to an event, then we hope that you’ll join us this month and see what all the Buzz is all about.

Read More
investmaryland-prizes-collage-image

InvestMaryland Challenge Prizes! – Startup Business Competition

By News Archive

investmaryland-prizes-collage-image

In 2014, startups took home nearly $1M in cash and prizes from the InvestMaryland Challenge. For 2015 we have new categories and are racking up partner prizes like cash grants, incubator space, legal advice and consulting services.

Start your application today! Applications are due December 12th.

$100,000 Grand Prize Categories

  • IT HARDWARE/SOFTWARE
    Enterprise Software, Data Analytics, Social Media & Apps, E-Commerce and Marketing/ADTECH.
  • DEFENSE & SECURITY
    Cybersecurity, Unmanned Systems, Defense, Communications Infrastructure, Public Infrastructure and Grid Security.
  • LIFE SCIENCES
    Biopharmaceuticals, Medical Devices & Diagnostics, Nutraceuticals, Agriculture Bio & Aquaculture and Healthcare IT.
  • SUSTAINABILTY & EXPLORATION
    EdTech, Energy, Solar Power, Space & Satellite Technologies, Climate Change/Weather, Water Management and Materials Science.
Read More

118th Edition – October 7, 2014

By BHI Weekly Newsletter Archives






You’re receiving this newsletter because of your interest in BioHealth Innovation
Having trouble viewing this email? View it in your browser.





Follow us on YouTube Follow us on Twitter





EAGB Partner in Regional BioHealth Commercialization Lauches New $50 Million Gap Fund – GreaterBaltimore

bhi-eagb-logo

BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today that venture capitalist, Tania Fernandez, Ph.D., has joined the BHI team as a strategic advisor. Dr. Fernandez will be a member of the management team for a new BioHealth Gap Fund, which will provide up to $50 million in seed and early-stage equity investments to therapeutics, medical device, diagnostics, and health IT companies in Maryland. Additional BioHealth Gap Fund management team members include Richard Bendis, Ram Aiyar, Todd Chappell, and Ken Malone, who each bring domain knowledge and industry access to the fund.

“Dr. Fernandez has ten years of experience as a venture capitalist in the life sciences/biotechnology industry. Her work in Silicon Valley, along with her research experience at the National Cancer Institute, makes her a tremendous asset to the BHI team,” said Richard Bendis, BHI President & CEO. “Dr. Fernandez brings a West Coast investment perspective, and she will have an active role in helping to manage the BioHealth Gap Fund. She will also support our BHI Entrepreneurs-in-Residence and clients: helping our startups to grow and raise strategic funding.”

back to top Back to top



Emergent BioSolutions to manufacture new anthrax vaccine

emergent-logo

The next generation of the nation’s only anthrax vaccine will be made in Lansing, an executive for Emergent BioSolutions Inc. said Tuesday.

There won’t be any new jobs as a direct result of the $29 million federal contract Emergent received earlier this month for production of the new drug, Adam Havey, president of the company’s biodefense division, said. But the new version of the vaccine will help keep current employees working.

back to top Back to top



Sucampo goes all-in on Amitiza with new DTC effort – Medical Marketing and Media

sucampo-logo

For the majority of drugs, end-of-lifecycle planning usually involves a reining-in of marketing costs. But Sucampo CEO Peter Greenleaf is doing the exact opposite. In the firm’s second-quarter earnings call, he announced the company is “doubling-down” on Amitiza, the constipation treatment which has been on the market for eight years and which will soon face the threat of generic competition.

Amitiza owns just 1% of the overall constipation market, which includes a number of OTC options, a representative for the drugmaker told MM&M. Sucampo co-markets Amitiza with Takeda.

back to top Back to top



Becton Dickinson to buy CareFusion for $12 billion in cash, stock | Reuters

becton-dickinson-bc

Medical equipment supplier Becton Dickinson & Co (BDX.N) has agreed to buy CareFusion Corp (CFN.N), a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcare sector deal.

Becton said on Sunday it would pay a total of $58.00 a share – $49.00 in cash and 0.0777 of a share of Becton Dickinson – for each share of CareFusion, representing a premium of 26 percent to the closing price on Oct. 3.

back to top Back to top



Roche Presents Data on Cancer Immunotherapy Candidate – October 3, 2014 – Zacks.com

roche-logo

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.

Roche (RHHBY – Analyst Report) specializes in cancer drugs. Immunotherapy has received a lot of attention in recent times as pharmaceuticals majors focus their research and development efforts on the same.

back to top Back to top



GSK commits $5M to startups, academics that develop bioelectronics

gsk-glaxo-vert-logo

GlaxoSmithKline has just launched a $5 million Innovation Challenge Fund to advance open-access technology in the bioelectronics space.

The funding’s aimed toward biz-savvy academics and startups that are working to create a new class of treatments that aren’t necessarily pills or injections, but rather are mini implantable devices. GSK says:”The hope is that these devices could be programmed to read and correct the electrical signals that pass along the nerves of the body, to treat disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes.”

back to top Back to top



University of Maryland, UMBC team on new cyber security research center – Baltimore Business Journal

kirwin-willian-brit-usm-image

University of Maryland, Baltimore County, and University of Maryland, College Park will work with MITRE Corp. on a new cyber security research and development center in Montgomery County.

McLean, Va.-based MITRE was selected by the National Institute of Standards and Technology for a $29 million award to operate a new federally funded research and development center dedicated to cyber security. The center will be housed at the National Cybersecurity Center of Excellence in Montgomery County.

back to top Back to top



Tasly Pharmaceuticals, Inc. Attends Natural Products Expo East 2014

tasly-logo

Tasly Pharmaceuticals, Inc. made its official debut at the Natural Products Expo East 2014, held from September 17-20, 2014 in Baltimore, MD. As the leading East Cost trade show in the natural, healthy and organic products industry, attracting 22,000 professionals and representing 33% of the natural products industry, Expo East 2014 was a perfect opportunity for Tasly to introduce Deepure, its inaugural line of nutraceuticals. The line includes three condition-specific, whole-food and herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Re-Memory PLUS. All Deepure nutraceuticals are gluten-free and made without chemicals, preservatives, artificial colors, flavors, sweeteners, or gelatin. Deepure will be available in stores nationwide later this Fall.

Tasly also participated in two very attractive marketing and sponsorship opportunities located in New Products Pavilion, including Best of East Press Showcase and New Products Showcase.

back to top Back to top



NICE/UKTI Scientific Advice Seminar – October 28th, Washington, D.C.

uk-trade-logo

To attend a NICE/UKTI Scientific Advice Seminar for developers of devices and diagnostics.

Learn how to prepare for an evaluation by NICE, the UK’s health technology assessment body.

The seminar will cover:

  • “Value” from the perspective of NICE
  • How value propositions link to the need for specific evidence
  • The types of evidence considered by NICE
  • The general principles of health technology assessment (HTA)
  • Advantages of doing business in the UK

Who should attend?

  • Developers of medical technologies, in particular SMEs
  • Investors in the field of medical technologies
  • Anyone new to the world of health technology assessment
  • Academics, scientists, or clinicians who want to know more about how NICE assesses the value of innovative products

The seminar program is funded by UKTI to allow you free event registration (standard event rate – $550)

Read More
uk-trade-logo

NICE/UKTI Scientific Advice Seminar – October 28th, Washington, D.C.

By News Archive

uk-trade-logo

To attend a NICE/UKTI Scientific Advice Seminar for developers of devices and diagnostics.

Learn how to prepare for an evaluation by NICE, the UK’s health technology assessment body.

The seminar will cover:

  • “Value” from the perspective of NICE
  • How value propositions link to the need for specific evidence
  • The types of evidence considered by NICE
  • The general principles of health technology assessment (HTA)
  • Advantages of doing business in the UK

Who should attend?

  • Developers of medical technologies, in particular SMEs
  • Investors in the field of medical technologies
  • Anyone new to the world of health technology assessment
  • Academics, scientists, or clinicians who want to know more about how NICE assesses the value of innovative products

The seminar program is funded by UKTI to allow you free event registration (standard event rate – $550)

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.